Sponsors, CROs and academic research teams choosing an eCOA platform for a regulated clinical trial.
Scope Electronic clinical outcome assessment (eCOA) platforms that capture patient-reported (ePRO), clinician-reported, observer-reported and performance outcomes in regulated clinical trials, as a sponsor, CRO or academic research team would shortlist them.
These notes describe the products in the eCOA guide.
Castor
Best for
Biotech, device and academic teams that want eCOA, eConsent and EDC in one platform with a self-service option
What to consider
Castor offers a validated instrument library with licensing handled by its services team, self-service builds that go live in weeks and a published pricing process with an entry package for early-stage companies. Its global reach and regulatory track record are smaller than the enterprise platforms'.
Global pivotal trials that combine eCOA with cardiac, respiratory, imaging or sensor endpoints
What to consider
Clario has the deepest enterprise eCOA profile here: studies in 120+ countries and 100+ languages, a named eCOA science team and pre-validated assessment libraries. It says it has supported 70% of FDA and EMA new drug approvals since 2015 across its endpoints. Builds are delivered by Clario and prices are not published.
Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.
Expand a feature definition or support note for context and its original source.
Castor vs Clario (eCOA): category feature evidence and sources. Products are not ranked.
Category feature
Castor
Clario
Validated instrument library and licensingFeature definitions
Supported
A library of outcome-assessment instruments is documented.
Extended support
A validated or instrument-author-approved library plus managed instrument licensing are documented.
Castor
Extended support
Library of validated instruments (EORTC, FACT-G, EQ-5D, SF-36, PROMIS); Professional Services manages scale licensing and validation; library size not published.
Part 11 and GxP compliance are stated; approval counts are not published.
Clario
Supported
States it has supported 70% of FDA and EMA new drug approvals since 2015 (company-wide, all endpoint types); ISO 27001:2022 and SOC 2 Type II are published separately.
The note reports studies across countries and languages.
Capture modes and integrationsFeature definitions
Supported
Electronic outcome capture and a connection to another trial system or device are documented.
Extended support
Capture on participant-owned and provisioned devices plus wearable or sensor integration are documented.
Castor
Supported
BYOD app, browser, SMS and messaging apps, site tablet mode and provisioned devices; integrates with major EDCs via REST API and webhooks. Wearable or sensor capture not documented.
Self-service builds go live in weeks; managed builds reach UAT in four to eight weeks.
Clario
Supported
eCOA Swift deploys early-phase oncology trials in as little as 2 weeks and Rapid Start offers pre-configured assessments; builds are vendor-delivered, no self-service designer published.
Vendor-delivered oncology deployment timing is stated; a self-service designer is not documented.
Published pricing and termsFeature definitions
Supported
A production pricing basis, model or contract terms beyond a sales contact are published.
Extended support
Numerical production prices or a free production option with its conditions are published.
Castor
Supported
Pricing process published: itemized, fixed-scope proposal with change-control terms within 5 business days, plus a Castor Essentials package for early-stage companies; no prices.